CIGB-814 (single-dose group)

Phase 1Small molecule

YYi Fang

CIGB-814 (single-dose group) is one of 4 small molecule programs targeting PK/PD. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PK/PDRecruiting

PK/PDPhase 1

Recruiting

Competition

Competitive Landscape

5 competitors in PK/PD

#DrugCompanyPhaseTrials

Oricar-017

OOriCell Therapeutics Co., Ltd.

Phase 1

1 2

In1011-N17

IiN Therapeutics Co., Ltd.

Phase 1

2 3

CIGB-814 (single-dose group)

YYi Fang

Phase 1

1 4

Temocillin

AAssistance Publique - Hôpitaux de Paris

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

PK/PD1 trial

Safety, Tolerability, and PK/PD of CIGB-814 in Chinese Health Participants

Recruiting·YYi Fang·Phase 1·NCT07182656·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CIGB-814 (single-dose group). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CIGB-814 (single-dose group) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CIGB-814 (single-dose group). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Yi Fang company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: YYi Fang

CIGB-814 (single-dose group)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

PK/PD1 trial

References

Drug Info

Quick Facts

Related News